Diabetic Biomarkers Concordance Compared in South African Blacks
|
By LabMedica International staff writers Posted on 28 Jun 2021 |

Image: The D-10 Hemoglobin Testing System provides comprehensive, automated hemoglobin testing in a compact footprint, combining HbA1c and HbA2/F/A1c testing on a single platform (Photo courtesy of Bio-Rad)
Sub-Saharan Africa is projected to experience a significant increase in the prevalence of diabetes mellitus by in the near future and accurate, comparable prevalence estimates will be essential to planning and monitoring by public health authorities.
Diagnosis based on glycated hemoglobin (HbA1c) is attractive because it provides an integrated assessment of glycemic status over the preceding three months and has low analytical variability, but the extent to which this single threshold may be adopted in all sub-Saharan African populations is questionable. Existing data suggest that in individuals of African descent, HbA1c may be higher for any given degree of glycaemia than in individuals of European descent.
A large international team of medical scientists led by those at the University of the Witwatersrand (Johannesburg, South Africa) included in a study 765 black individuals aged 40–70 years and with no history of diabetes. The team investigated concordance between hemoglobin A1c (HbA1c)-defined diabetes and fasting plasma glucose (FPG)-defined diabetes in a black South African population with a high prevalence of obesity.
Capillary blood samples were tested for hemoglobin at point of collection using the Haemocue Hb 201+analyser (Haemocue, Ängelholm, Sweden). Whole blood was analyzed for HbA1c using high-performance liquid chromatography on the Bio-Rad D-10 (Bio-Rad Laboratories, Hercules, CA, USA) with a reportable range of 3.8%–18.5%. Plasma was analyzed for glucose using colorimetric methods on the Randox Plus clinical chemistry analyzer (Randox, Crumlin, UK) with a range of 0.36–35 mmol/L. Serum insulin assays were performed on the Immulite 1000 chemistry analysis system (Siemens Healthineers, Erlangen, Germany), using a solid-phase, enzyme-labeled chemiluminescent immunometric assay (range 2–300 μIU/mL).
The investigators reported that the prevalence of HbA1c-defined diabetes was four times the prevalence of FPG-defined diabetes (17.5% versus 4.2%). Classification was discordant in 15.7% of participants, with 111 individuals (14.5%) having HbA1c-only diabetes. Median body mass index, waist and hip circumference, waist-to-hip ratio, subcutaneous adipose tissue and Homoeostatic Model Assessment of Insulin Resistance (HOMA-IR) in participants with HbA1c-only diabetes were similar to those in participants who were normoglycemic by both biomarkers and significantly lower than in participants with diabetes by both biomarkers. HOMA-IR and fat distribution explained additional HbA1c variance beyond glucose and age only in women.
The authors concluded that concordance was poor between HbA1c and FPG in diagnosis of diabetes in black South Africans, and participants with HbA1c-only diabetes phenotypically resembled normoglycemic participants. Further work is necessary to determine which of these parameters better predicts diabetes-related morbidities in this population and whether a population-specific HbA1c threshold is necessary. The study was published on June 17, 2021 in the journal BMJ OPEN.
Related Links:
University of the Witwatersrand
Haemocue
Bio-Rad Laboratories
Randox
Siemens Healthineers
Diagnosis based on glycated hemoglobin (HbA1c) is attractive because it provides an integrated assessment of glycemic status over the preceding three months and has low analytical variability, but the extent to which this single threshold may be adopted in all sub-Saharan African populations is questionable. Existing data suggest that in individuals of African descent, HbA1c may be higher for any given degree of glycaemia than in individuals of European descent.
A large international team of medical scientists led by those at the University of the Witwatersrand (Johannesburg, South Africa) included in a study 765 black individuals aged 40–70 years and with no history of diabetes. The team investigated concordance between hemoglobin A1c (HbA1c)-defined diabetes and fasting plasma glucose (FPG)-defined diabetes in a black South African population with a high prevalence of obesity.
Capillary blood samples were tested for hemoglobin at point of collection using the Haemocue Hb 201+analyser (Haemocue, Ängelholm, Sweden). Whole blood was analyzed for HbA1c using high-performance liquid chromatography on the Bio-Rad D-10 (Bio-Rad Laboratories, Hercules, CA, USA) with a reportable range of 3.8%–18.5%. Plasma was analyzed for glucose using colorimetric methods on the Randox Plus clinical chemistry analyzer (Randox, Crumlin, UK) with a range of 0.36–35 mmol/L. Serum insulin assays were performed on the Immulite 1000 chemistry analysis system (Siemens Healthineers, Erlangen, Germany), using a solid-phase, enzyme-labeled chemiluminescent immunometric assay (range 2–300 μIU/mL).
The investigators reported that the prevalence of HbA1c-defined diabetes was four times the prevalence of FPG-defined diabetes (17.5% versus 4.2%). Classification was discordant in 15.7% of participants, with 111 individuals (14.5%) having HbA1c-only diabetes. Median body mass index, waist and hip circumference, waist-to-hip ratio, subcutaneous adipose tissue and Homoeostatic Model Assessment of Insulin Resistance (HOMA-IR) in participants with HbA1c-only diabetes were similar to those in participants who were normoglycemic by both biomarkers and significantly lower than in participants with diabetes by both biomarkers. HOMA-IR and fat distribution explained additional HbA1c variance beyond glucose and age only in women.
The authors concluded that concordance was poor between HbA1c and FPG in diagnosis of diabetes in black South Africans, and participants with HbA1c-only diabetes phenotypically resembled normoglycemic participants. Further work is necessary to determine which of these parameters better predicts diabetes-related morbidities in this population and whether a population-specific HbA1c threshold is necessary. The study was published on June 17, 2021 in the journal BMJ OPEN.
Related Links:
University of the Witwatersrand
Haemocue
Bio-Rad Laboratories
Randox
Siemens Healthineers
Latest Clinical Chem. News
- Screening After Pneumococcal Disease May Reveal Undiagnosed Blood Cancer or Immune Disorders
- Label-Free Platform Combines Microfluidics and AI for Circulating Tumor Cell Analysis
- Rapid D-Dimer Assay Supports Exclusion and Monitoring of Serious Clotting Conditions
- Global Survey Underscores Need to Standardize Bone Biomarker Testing
- Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke
- Noninvasive Earwax Test Aims to Detect Meniere’s Disease
- Blood Biomarker Patterns Could Support Monitoring of Anti-Amyloid Treatment
- Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
- Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain
- First-of-Its-Kind Rapid Blood Test Gains CE Mark to Support Prehospital Stroke Triage
- Multi-Cancer Blood Test Expands Detection to Cancers Lacking Routine Screening Options
- Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes
- Blood Test Patterns Improve Cancer Risk Assessment in Primary Care
- Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection
- Machine Learning Supports Targeted Screening for Elevated Lipoprotein(a)
- Blood Antibody Linked to Lower Depression and PTSD Symptoms After Brain Injury
Channels
Molecular Diagnostics
view channel
Urine-Based RNA Improves Bladder Cancer Detection and Monitoring
Bladder cancer affects about 85,000 people in the United States each year and is prone to recurrence. Diagnosis and surveillance commonly rely on cystoscopy, an endoscopic examination that can miss up... Read more
Blood RNA Panel Predicts Lung Cancer Risk Years Before Diagnosis
Lung cancer may begin developing during a preclinical period when the disease remains clinically undetected, creating a challenge for identifying individuals at elevated risk years before diagnosis.... Read moreHematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read moreImmunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read moreMicrobiology
view channel
FDA-Cleared Multiplex PCR Test Detects 13 Respiratory Pathogens in a Single Sample
Respiratory tract infections can be difficult to distinguish at presentation because many cause overlapping, nonspecific symptoms and are initially grouped as influenza-like illnesses. Causes span a range... Read more
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read morePathology
view channel
Genomic Classifier Predicts Benefit From Adding Hormone Therapy to Salvage Prostate Radiation
Men who have undergone prostatectomy for prostate cancer may later develop a detectable or rising prostate-specific antigen, prompting salvage radiation therapy. A key challenge is determining who is most... Read more
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read moreTechnology
view channelLaser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns
Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more
Laser-Enhanced Assay Boosts Sensitivity for Colorectal Cancer Biomarker Detection
Colorectal cancer is the third most commonly diagnosed cancer and the second leading cause of cancer-related death worldwide. Early detection remains critical, but cancer biomarkers can produce only faint... Read moreIndustry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more







